12:00 AM
 | 
Jun 09, 2003
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OvaRex MAb: Phase II data; Phase III

In a Phase II trial in 145 patients, the median time to disease relapse for OvaRex patients was 13.3 months compared to 10.3 months for placebo, not a significant difference. Researchers said further analysis revealed a well-defined population...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >